A Phase 3 interventional study of Dolutegravir in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-25.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects who fulfill eligibility requirements will receive dolutegravir (DTG) 50 mg once daily in combination with the fixed dose dual nucleoside reverse transcripatase inhibitor(NRTI) abacavir/lamivudine (ABC/3TC) for 96 weeks. One pair of pharmacokinetic (PK) samples in plasma and cerebral spinal fluid (CSF) (matching time) for determination of DTG concentration will be collected at Week 2 and Week 16. Samples for plasma HIV-1 RNA will be collected at Baseline and various time points throughout the study and samples for HIV-1 RNA levels in the CSF will be collected at Baseline, Week 2 and Week 16. Safety, additional measures of antiviral activity and development of viral resistance will also be evlauated. The primary analysis will take place after the last subject completes 16 weeks on therapy; additional analyses will be conducted after the last subject completes Weeks 2 and 96 (end of study).
ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects who meet all screening requirements may enter the study and initiate treatment as soon as all screening procedures have been completed and results are available and on file. The 14-day screening period may be extended to 28 days to allow receipt of all Screening assessment results and to accommodate scheduling.
Subjects who fulfill eligibility requirements will receive dolutegravir (DTG) 50 mg once daily in combination with the fixed dose dual nucleoside reverse transcripatase inhibitor(NRTI) abacavir/lamivudine ABC/3TC for 96 weeks. One pair of pharmacokinetic (PK) samples in plasma and CSF (matching time) for determination of DTG concentration will be collected at Week 2 and Week 16. Samples for plasma HIV-1 RNA will be collected at Baseline and various time points throughout the study and samples for HIV-1 RNA levels in the CSF will be collected at Baseline, Week 2 and Week 16. Safety, additional measures of antiviral activity and development of viral resistance will also be evlauated. The primary analysis will take place after the last subject completes 16 weeks on therapy; additional analyses will be conducted after the last subject completes Weeks 2 and 96 (end of study).
Subjects are considered to have completed the study if they remain on therapy (i.e., have not permanently discontinued investigational product [IP]) and complete the Treatment Phase, including the Week 96 visit.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 13 is below the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
Drug: Dolutegravir
50mg Once Daily
The Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16
Cerebrospinal fluid (CSF) is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma pharmacokinetic (PK) sampling. The ratio (presented as a percentage) of CSF DTG concentration over paired plasma total DTG concentration (RCSF_plasma) was calculated at the Week 2 and Week 16 visits.
Time frame: Week 2 and Week 16
Total DTG Plasma Concentrations at Week 2 and Week 16
Total plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.
Time frame: Week 2 and Week 16
Unbound DTG Plasma Concentrations at Week 2 and Week 16
Unbound (free, not bound to cellular proteins) plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.
Time frame: Week 2 and Week 16
Plasma DTG Unbound Fraction at Week 2 and Week 16
The unbound fraction of DTG in plasma (presented as a percentage of unbound \[i.e., free DTG not bound to cellular proteins\] DTG plasma concentration over paired plasma total DTG concentration) was calculated at the Week 2 and Week 16 visits.
Time frame: Week 2 and Week 16
DTG Concentrations in CSF at Weeks 2 and Week 16
CSF is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma PK sampling. DTG concentration in CSF were calculated at the Week 2 and Week 16 visits.
Time frame: Week 2 and Week 16
Number of Participants With Plasma HIV-1 RNA <50 Copies Per Milliliter (c/mL) at Baseline and Weeks 2, 4, 8, 12, and 16
HIV-1 RNA response in plasma was measured as the number of participants with HIV-1 RNA less than 50 c/mL at Baseline, Week 2, Week 4, Week 8, Week 12, and Week 16.
Time frame: Baseline; Weeks 2, 4, 8, 12, and 16
Absolute Values and Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) Levels at Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
The plasma samples were collected at the Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96 visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
Number of Participants With CSF HIV-1 RNA <50 Copies/Milliliter (c/mL) at Baseline, Week 2, and Week 16
The antiviral activity of dolutegravir in CSF over time was measured as the number of participants with HIV-1 RNA \<50 copies/milliliter (c/mL).
Time frame: Baseline, Week 2, and Week 16
Absolute Values and Change From Baseline in CSF HIV-1 RNA Levels at Week 2 and Week 16
The antiviral activity of dolutegravir in CSF over time was measured as absolute values and change from Baseline in HIV-1 RNA levels in CSF at Week 2 and Week 16. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline, Week 2, and Week 16
Number of Participants With the Indicated Number of Copies of HIV-1 RNA in Both the CSF and Plasma at Baseline, Week 2, and Week 16
The relationship between HIV-1 RNA suppression in plasma and the CSF was measured as a comparison and as a change in the number of participants in the cross tabulation of \<50 copies/mL in plasma, \<50 copies/mL in CSF, \>=50 copies/mL in plasma, and \>=50 copies/mL in CSF at Baseline, Week 2, and Week 16.
Time frame: Baseline, Week 2, and Week 16
Pearson Correlation Between CSF DTG Concentration and Absolute Values and Change From Baseline (CFB) in CSF HIV-1 RNA at Week 2, Week 16, and Overall
The Pearson Correlation Coefficient is a measure of the correlation between CSF DTG concentrations and absolute values/changes from Baseline in CSF HIV-1 RNA at Week 2 and Week 16. CSF HIV-1 RNA is measured as log10 copies per milliliter (copies/mL).
Time frame: From Baseline to Week 16
Absolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
The absolute value for CD4+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96
Absolute Values and Change From Baseline in Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 12, 16, 24, 48, and 96
The absolute value for CD48+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 12, Week 16, Week 24, Week 48, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 4, 12, 16, 24, 48, and 96
Number of Participants With Post-Baseline HIV-1-associated Conditions, Including Recurrences
The number of participants who reported a new or recurrent Centers for Disease Control and Prevention (CDC) Class B or Class C condition was assessed from Baseline though the date the last participant completed Week 96 + the follow-up visit (if applicable). Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition.
Time frame: Baseline through the date the last participant completed Week 96 + follow-up visit (if applicable)
The Numbers of Participants (Par.) With Clinical Adverse Events or Laboratory Abnormalities
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs/SAEs. Any abnormal laboratory test result (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., electrocardiograms \[ECGs\], radiological scans, vital sign measurements), including those that worsen from Baseline, and were felt to be clinically significant in the medical and scientific judgment of the investigator, were recorded as AEs or SAEs. Clinically suspected cases of hypersensitivity to ABC were also SAEs.
Time frame: Baseline (BL) through the date the last participant completed Week (W) 96 + the follow-up visit (if applicable)
Number of Participants With Treatment-emergent Genotypic and Phenotypic Resistance to DTG and Other Antiretroviral Therapy (ART)
The number of participants with treatment-emergent genotypic and phenotypic resistance to integrase inhibitors (INIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transctiptase inhibitors (NNRTIs), and protease inhibitors (PIs) was assessed.
Time frame: Baseline through the date the last participant completed Week 96
| Milestone | Dolutegravir 50 mg OD |
|---|---|
| Started | 13 |
| Completed | 11 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 1 |
Cerebrospinal fluid (CSF) is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma pharmacokinetic (PK) sampling. The ratio (presented as a percentage) of CSF DTG concentration over paired plasma total DTG concentration (RCSF_plasma) was calculated at the Week 2 and Week 16 visits.
| percentage | Dolutegravir 50 mg OD |
|---|---|
| Week 2, n=11 | 0.516 (0.115 to 0.658) |
| Week 16, n=12 | 0.412 (0.299 to 2.04) |
Total plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.
| Micrograms per milliliter (µg/mL) | Dolutegravir 50 mg OD |
|---|---|
| Week 2 | 3.36 (2.09 to 5.28) |
| Week 16 | 3.21 (0.64 to 4.92) |
Unbound (free, not bound to cellular proteins) plasma DTG concentrations were calculated at the Week 2 and Week 16 visits.
| Nanograms per milliliter (ng/mL) | Dolutegravir 50 mg OD |
|---|---|
| Week 2 | 17.1 (10.3 to 24.0) |
| Week 16 | 23.9 (3.81 to 32.1) |
The unbound fraction of DTG in plasma (presented as a percentage of unbound \[i.e., free DTG not bound to cellular proteins\] DTG plasma concentration over paired plasma total DTG concentration) was calculated at the Week 2 and Week 16 visits.
| Percentage | Dolutegravir 50 mg OD |
|---|---|
| Week 2 | 0.488 (0.333 to 0.655) |
| Week 16 | 0.701 (0.488 to 4.30) |
CSF is a clear, colorless bodily fluid produced in the choroid plexus of the brain. The CFS samples were collected at the Week 2 and Week 16 visits, within 1 hour of plasma PK sampling. DTG concentration in CSF were calculated at the Week 2 and Week 16 visits.
| Nanograms per milliliter (ng/mL) | Dolutegravir 50 mg OD |
|---|---|
| Week 2, n=11 | 18.2 (4.0 to 23.2) |
| Week 16, n=12 | 13.2 (3.7 to 18.3) |
HIV-1 RNA response in plasma was measured as the number of participants with HIV-1 RNA less than 50 c/mL at Baseline, Week 2, Week 4, Week 8, Week 12, and Week 16.
| participants | Dolutegravir 50 mg OD |
|---|---|
| Baseline | 0 |
| Week 2 | 4 |
| Week 4 | 6 |
| Week 8 | 8 |
| Week 12 | 10 |
| Week 16 | 10 |
The plasma samples were collected at the Week 2, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96 visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| log10 copies/mL | Dolutegravir 50 mg OD |
|---|---|
| Absolute value, Baseline, n=13 | 4.73 (3.60 to 6.57) |
| Absolute value, Week 2, n=12 | 2.05 (1.59 to 2.99) |
| Change from Baseline, Week 2, n=12 | -2.53 (-3.70 to -2.01) |
| Absolute value, Week 4, n=12 | 1.67 (1.59 to 2.49) |
| Change from Baseline, Week 4, n=12 | -3.04 (-4.08 to -2.01) |
| Absolute Value, Week 8, n=12 | 1.59 (1.59 to 2.48) |
| Change from Baseline, Week 8, n=12 | -3.10 (-4.09 to -2.01) |
| Absolute value, Week 12, n=12 | 1.59 (1.59 to 2.36) |
| Change from Baseline, Week 12, n=12 | -3.04 (-4.20 to -2.01) |
| Absolute value, Week 16, n=12 | 1.59 (1.59 to 2.37) |
| Change from Baseline, Week 16, n=12 | -3.04 (-4.19 to -2.01) |
| Absolute Value, Week 24, n=12 | 1.59 (1.59 to 2.21) |
| Change from Baseline, Week 24, n=12 | -3.11 (-4.35 to -2.01) |
| Absolute value, Week 36, n=11 | 1.59 (1.59 to 1.62) |
| Change from Baseline, Week 36, n=11 | -3.08 (-3.89 to -2.01) |
| Absolute value, Week 48, n=11 | 1.59 (1.59 to 2.10) |
| Change from Baseline, Week 48, n=11 | -3.00 (-3.78 to -2.01) |
| Absolute value, Week 60, n=11 | 1.59 (1.59 to 2.19) |
| Change from Baseline, Week 60, n=11 | -3.00 (-3.89 to -2.01) |
| Absolute value, Week 72, n=11 | 1.59 (1.59 to 2.01) |
| Change from Baseline, Week 72, n=11 | -3.08 (-3.78 to -2.01) |
| Absolute value, Week 84, n=11 | 1.59 (1.59 to 1.72) |
| Change from Baseline, Week 84, n=11 | -3.08 (-3.89 to -1.88) |
| Absolute value, Week 96, n=11 | 1.59 (1.59 to 3.05) |
| Change from Baseline, Week 96, n=11 | -3.08 (-3.78 to -0.55) |
The antiviral activity of dolutegravir in CSF over time was measured as the number of participants with HIV-1 RNA \<50 copies/milliliter (c/mL).
| participants | Dolutegravir 50 mg OD |
|---|---|
| Baseline, n=13 | 1 |
| Week 2, n=12 | 7 |
| Week 16, n=11 | 11 |
The antiviral activity of dolutegravir in CSF over time was measured as absolute values and change from Baseline in HIV-1 RNA levels in CSF at Week 2 and Week 16. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| log10 c/mL | Dolutegravir 50 mg OD |
|---|---|
| Absolute value, Baseline, n=13 | 3.64 (1.46 to 5.60) |
| Absolute value, Week 2, n=12 | 0.98 (0.00 to 3.30) |
| Change from Baseline, Week 2, n=12 | -2.19 (-3.11 to -1.29) |
| Absolute value, Week 16, n=11 | 0.00 (0.00 to 0.70) |
| Change from Baseline, Week 16, n=11 | -3.42 (-5.60 to -1.46) |
The relationship between HIV-1 RNA suppression in plasma and the CSF was measured as a comparison and as a change in the number of participants in the cross tabulation of \<50 copies/mL in plasma, \<50 copies/mL in CSF, \>=50 copies/mL in plasma, and \>=50 copies/mL in CSF at Baseline, Week 2, and Week 16.
| participants | Dolutegravir 50 mg OD |
|---|---|
| Baseline, CSF<50 c/mL, Plasma<50 c/mL, n=13 | 0 |
| Baseline, CSF<50 c/mL, Plasma>=50 c/mL, n=13 | 1 |
| Baseline, CSF>=50 c/mL, Plasma<50 c/mL, n=13 | 0 |
| Baseline, CSF>=50 c/mL, Plasma>=50 c/mL, n=13 | 12 |
| Week 2, CSF<50 c/mL, Plasma<50 c/mL, n=12 | 4 |
| Week 2, CSF<50 c/mL, Plasma>=50 c/mL, n=12 | 3 |
| Week 2, CSF>=50 c/mL, Plasma<50 c/mL, n=12 | 0 |
| Week 2, CSF>=50 c/mL, Plasma>=50 c/mL, n=12 | 5 |
| Week 16, CSF<50 c/mL, Plasma<50 c/mL, n=11 | 9 |
| Week 16, CSF<50 c/mL, Plasma>=50 c/mL, n=11 | 2 |
| Week 16, CSF>=50 c/mL, Plasma<50 c/mL, n=11 | 0 |
| Week 16, CSF>=50 c/mL, Plasma>=50 c/mL, n=11 | 0 |
The Pearson Correlation Coefficient is a measure of the correlation between CSF DTG concentrations and absolute values/changes from Baseline in CSF HIV-1 RNA at Week 2 and Week 16. CSF HIV-1 RNA is measured as log10 copies per milliliter (copies/mL).
| Pearson Correlation Coefficient | Dolutegravir 50 mg OD |
|---|---|
| Week 2, Absolute Log10 CSF HIV-1 RNA, n=11 | 0.567 (0.062 to 0.841) |
| Week 2, CFB Log10 CSF HIV-1, n=11 | 0.007 (-0.518 to 0.529) |
| Week 16, Absolute Log10 CSF HIV-1 RNA, n=11 | -0.775 (-0.924 to -0.423) |
| Week 16, CFB Log10 CSF HIV-1, n=11 | -0.354 (-0.740 to 0.209) |
| Overall, Absolute Log10 CSF HIV-1 RNA, n=11 | 0.517 (0.193 to 0.740) |
| Overall, CFB Log10 CSF HIV-1, n=11 | 0.106 (-0.265 to 0.449) |
The absolute value for CD4+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| cells/mm^3 | Dolutegravir 50 mg OD |
|---|---|
| Absolute CD4+ cell count, Baseline, n=13 | 260 (152 to 863) |
| Absolute CD4+ cell count, Week 4, n=12 | 578 (374 to 903) |
| Absolute CD4+ cell count, Week 8, n=12 | 645 (364 to 1118) |
| Absolute CD4+ cell count, Week 12, n=12 | 589 (303 to 1144) |
| Absolute CD4+ cell count, Week 16, n=12 | 573 (436 to 1156) |
| Absolute CD4+ cell count, Week 24, n=12 | 634 (448 to 1339) |
| Absolute CD4+ cell count, Week (Wk) 36, n=11 | 706 (534 to 1351) |
| Absolute CD4+ cell count, Week 48, n=11 | 666 (537 to 939) |
| Absolute CD4+ cell count, Week 60, n=11 | 702 (567 to 1266) |
| Absolute CD4+ cell count, Week 72, n=11 | 823 (620 to 1315) |
| Absolute CD4+ cell count, Week 84, n=11 | 907 (512 to 1341) |
| Absolute CD4+ cell count, Week 96, n=11 | 843 (339 to 1436) |
| Change from Baseline CD4+ cell count, Week 4, n=12 | 162 (-158 to 365) |
| Change from Baseline CD4+ cell count, Week 8, n=12 | 247 (44 to 551) |
| Change from Baseline CD4+ cell count, Wk 12, n=12 | 263 (-17 to 500) |
| Change from Baseline CD4+ cell count, Wk 16, n=12 | 226 (-248 to 629) |
| Change from Baseline CD4+ cell count, Wk 24, n=12 | 264 (86 to 762) |
| Change from Baseline CD4+ cell count, Wk 36, n=11 | 480 (174 to 774) |
| Change from Baseline CD4+ cell count, Wk 48, n=11 | 311 (-80 to 541) |
| Change from Baseline CD4+ cell count, Wk 60, n=11 | 382 (5 to 708) |
| Change from Baseline CD4+ cell count, Wk 72, n=11 | 519 (260 to 651) |
| Change from Baseline CD4+ cell count, Wk 84, n=11 | 543 (94 to 792) |
| Change from Baseline CD4+ cell count, Wk 96, n=11 | 467 (-65 to 859) |
The absolute value for CD48+ cell count (cells per millimeters cubed \[mm\^3\]) was assessed at Baseline, Week 4, Week 12, Week 16, Week 24, Week 48, and Week 96. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| cells/mm^3 | Dolutegravir 50 mg OD |
|---|---|
| Absolute CD8+ cell count, Baseline, n=13 | 757 (276 to 2945) |
| Absolute CD8+ cell count, Week 4, n=12 | 874 (542 to 1984) |
| Absolute CD8+ cell count, Week 12, n=12 | 865 (419 to 1472) |
| Absolute CD8+ cell count, Week 16, n=12 | 706 (478 to 1818) |
| Absolute CD8+ cell count, Week 24, n=11 | 876 (434 to 1634) |
| Absolute CD8+ cell count, Week 48, n=11 | 708 (530 to 1318) |
| Absolute CD8+ cell count, Week 96, n=11 | 842 (249 to 1582) |
| Change from Baseline CD8+ cell count, Week 4, n=12 | 104 (-1123 to 1060) |
| Change from Baseline CD8+ cell count,Week 12, n=11 | -53 (-1627 to 631) |
| Change from Baseline CD8+ cell count,Week 16, n=11 | -35 (-1614 to 684) |
| Change from Baseline CD8+ cell count,Week 24, n=11 | 235 (-418 to 710) |
| Change from Baseline CD8+ cell count,Week 48, n=11 | 106 (-747 to 441) |
| Change from Baseline CD8+ cell count,Week 96, n=11 | 85 (-424 to 677) |
The number of participants who reported a new or recurrent Centers for Disease Control and Prevention (CDC) Class B or Class C condition was assessed from Baseline though the date the last participant completed Week 96 + the follow-up visit (if applicable). Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition.
| participants | Dolutegravir 50 mg OD |
|---|---|
| New CDC Category B event | 0 |
| Recurring CDC Category B event | 0 |
| New CDC Category C event | 0 |
| Recurring CDC Category C event | 0 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs/SAEs. Any abnormal laboratory test result (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., electrocardiograms \[ECGs\], radiological scans, vital sign measurements), including those that worsen from Baseline, and were felt to be clinically significant in the medical and scientific judgment of the investigator, were recorded as AEs or SAEs. Clinically suspected cases of hypersensitivity to ABC were also SAEs.
| participants | Dolutegravir 50 mg OD |
|---|---|
| Any AE | 13 |
| Clinical chemistry toxicities | 12 |
| Hematology toxicities | 3 |
| Abnormal ECG (clinically significant) | 0 |
The number of participants with treatment-emergent genotypic and phenotypic resistance to integrase inhibitors (INIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transctiptase inhibitors (NNRTIs), and protease inhibitors (PIs) was assessed.
| participants | Dolutegravir 50 mg OD |
|---|---|
| Treatment-emergent genotypic resistance | 0 |
| Treatment-emergent phenotypic resistance | 0 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the date the last participant completed Week 96+ follow-up visit (if applicable).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dolutegravir 50 mg OD | — | 2/13 (15.4%) | 13/13 (100%) |
| Event | Dolutegravir 50 mg OD |
|---|---|
| PharyngitisInfections and infestations | 1/13 |
| CholecystitisHepatobiliary disorders | 1/13 |
| Event | Dolutegravir 50 mg OD |
|---|---|
| HeadacheNervous system disorders | 7/13 |
| Upper respiratory tract infectionInfections and infestations | 5/13 |
| DiarrhoeaGastrointestinal disorders | 4/13 |
| HaemorrhoidsGastrointestinal disorders | 3/13 |
| FatigueGeneral disorders | 3/13 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/13 |
| Procedural painInjury, poisoning and procedural complications | 3/13 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/13 |
| FolliculitisInfections and infestations | 2/13 |
| PharyngitisInfections and infestations | 2/13 |
| Age, Continuous(Years) | Dolutegravir 50 mg OD |
|---|---|
| Mean | 40.2 ± 6.90 |
| Sex: Female, Male(Participants) | Dolutegravir 50 mg OD |
|---|---|
| Female | 0 |
| Male | 13 |
| Race/Ethnicity, Customized(participants) | Dolutegravir 50 mg OD |
|---|---|
| White | 13 |
| Baseline plasma human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA)(log10 copies/mL) | Dolutegravir 50 mg OD |
|---|---|
| Median | 4.73 (3.60 to 6.57) |
| Number of participants with Baseline plasma HIV-1 RNA <=100000 copies/mL and >100000 copies/mL(Participants) | Dolutegravir 50 mg OD |
|---|---|
| <=100000 copies/mL | 8 |
| >100000 copies/mL | 5 |
The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir